ID
32741
Description
Study ID: 107085 Clinical Study ID: GLP107085 Study Title: A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01406262 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2
Keywords
Versions (1)
- 11/14/18 11/14/18 -
Copyright Holder
GSK group of companies
Uploaded on
November 14, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
The Effect of Albiglutide on Cardiac Repolarisation Compared with Placebo 107085
Screening Visit: Eligibility and Admission
- StudyEvent: ODM
Description
Informed Consent
Description
Admission Criteria
Description
Protocol Date
Data type
date
Description
Did the subject meet all eligibility criteria?
Data type
boolean
Description
If No, please record reasons
Data type
text
Description
Date of Sponsor Approval
Data type
date
Similar models
Screening Visit: Eligibility and Admission
- StudyEvent: ODM